Orchid Pharma Ltd

Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Orchid Pharma Ltd

₹ 710 -0.25%
25 Jul - close price
orchidpharma.com BSE: 524372 NSE: ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]

Website BSE NSE
  • Market Cap ₹ 3,603 Cr.
  • Current Price ₹ 710
  • High / Low ₹ 1,998 / 604
  • Stock P/E 36.2
  • Book Value ₹ 250
  • Dividend Yield 0.00 %
  • ROCE 8.02 %
  • ROE 8.18 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 22.5% CAGR over last 5 years

Cons

  • Stock is trading at 2.84 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 7.04% over last 3 years.
  • Promoter holding has decreased over last 3 years: -20.1%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
178 131 165 160 210 183 199 221 217 244 223 217 237
152 119 147 146 170 161 175 185 188 212 192 191 209
Operating Profit 26 12 18 14 40 22 23 35 29 32 30 26 28
OPM % 14% 10% 11% 9% 19% 12% 12% 16% 13% 13% 14% 12% 12%
-0 3 6 9 34 2 8 8 13 8 8 8 4
Interest 4 8 9 8 7 6 4 4 3 4 3 4 4
Depreciation 27 22 18 8 7 8 8 9 8 8 9 9 9
Profit before tax -5 -14 -3 7 59 11 20 30 30 28 26 22 19
Tax % 0% 0% 0% 0% 0% 0% 0% 0% -10% -1% 0% 0% -0%
-7 -15 -5 8 59 9 20 29 33 29 27 21 22
EPS in Rs -1.61 -3.68 -1.32 1.86 14.49 1.85 3.90 5.80 6.50 5.79 5.37 4.10 4.39
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Sep 2013 18m Mar 2015 18m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,948 1,747 873 797 683 600 484 450 560 666 819 922
1,837 1,429 703 794 659 612 515 421 505 581 708 805
Operating Profit 110 317 171 3 24 -12 -31 29 55 84 111 117
OPM % 6% 18% 20% 0% 4% -2% -6% 7% 10% 13% 14% 13%
92 156 -28 -59 20 218 24 15 67 52 31 27
Interest 523 537 294 347 310 7 6 52 33 33 17 15
Depreciation 252 325 145 141 133 130 118 109 87 55 33 35
Profit before tax -573 -389 -296 -544 -399 69 -131 -117 2 48 92 96
Tax % -2% -49% -6% -9% -12% 0% 0% 0% 0% 0% -3% -0%
-560 -197 -279 -495 -353 69 -131 -117 -2 46 92 100
EPS in Rs -79.21 -23.06 -31.37 -55.69 -39.65 7.80 -32.11 -28.55 -0.48 11.35 18.17 19.65
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -6%
5 Years: 14%
3 Years: 18%
TTM: 13%
Compounded Profit Growth
10 Years: 9%
5 Years: 23%
3 Years: 249%
TTM: 8%
Stock Price CAGR
10 Years: 28%
5 Years: %
3 Years: 30%
1 Year: -50%
Return on Equity
10 Years: %
5 Years: 2%
3 Years: 7%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 70 85 89 89 89 89 41 41 41 41 51 51
Reserves 310 244 -40 -556 -881 -793 725 612 607 648 1,119 1,217
3,204 3,211 3,215 3,106 3,202 3,230 566 453 268 331 135 175
1,067 521 598 616 715 551 128 132 195 205 249 246
Total Liabilities 4,651 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 1,688
2,584 1,795 1,637 1,497 1,386 1,256 858 670 584 573 620 649
CWIP 360 282 280 288 272 278 26 7 10 46 31 64
Investments 1 1 1 1 1 0 0 15 45 44 46 50
1,706 1,984 1,944 1,470 1,467 1,542 576 544 472 561 857 925
Total Assets 4,651 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 1,688

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
168 -369 212 401 9 12 81 24 92 18 126 19
-986 1,334 -1 -176 -28 45 167 67 113 -31 -312 -27
664 -597 -286 -465 33 -0 -250 -165 -217 31 167 25
Net Cash Flow -153 367 -76 -240 15 57 -2 -74 -11 18 -19 18

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 34 54 130 75 64 73 51 110 111 118 87 96
Inventory Days 187 118 220 196 202 214 254 244 201 217 199 219
Days Payable 220 146 341 402 374 381 182 176 195 165 173 149
Cash Conversion Cycle -0 26 9 -130 -108 -94 123 179 117 170 113 166
Working Capital Days -113 86 97 -226 -505 -735 166 305 136 154 124 152
ROCE % -3% 1% 1% -4% -4% -5% -6% -5% -2% 5% 9% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
89.96% 89.96% 89.96% 72.40% 72.40% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84%
1.37% 0.86% 0.81% 8.58% 8.08% 4.14% 1.96% 1.42% 1.94% 2.53% 2.69% 1.39%
2.98% 3.94% 2.62% 13.48% 12.46% 14.51% 17.73% 18.93% 18.30% 19.00% 20.10% 19.43%
5.69% 5.22% 6.60% 5.54% 7.05% 11.52% 10.47% 9.82% 9.94% 8.63% 7.37% 9.34%
No. of Shareholders 32,71730,89429,52329,13229,19736,93136,72034,69536,36334,15834,30339,827

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls